Exploring the room for repurposed hydroxychloroquine to impede COVID-19: toxicities and multipronged combination approaches with pharmaceutical insights

Jain, A and Prajapati, SK and Tripathi, M and Raichur, AM and Kanwar, JR (2021) Exploring the room for repurposed hydroxychloroquine to impede COVID-19: toxicities and multipronged combination approaches with pharmaceutical insights. In: Expert Review of Clinical Pharmacology, 14 (6). pp. 715-734.

PDF Exp_Rev_Clin_Pharm_14-6_715-734_2021.pdf - Published Version Restricted to Registered users only Download (12MB) | Request a copy

Abstract

Introduction: SARS-CoV-2 has fatally affected the whole world with millions of deaths. Amidst the dilemma of a breakthrough in vaccine development, hydroxychloroquine (HCQ) was looked upon as a prospective repurposed candidate. It has confronted numerous controversies in the past few months as a chemoprophylactic and treatment option for COVID-19. Recently, it has been withdrawn by the World Health Organization for its use in an ongoing pandemic. However, its benefit/risk ratio regarding its use in COVID-19 disease remains poorly justified. An extensive literature search was done using Scopus, PubMed, Google Scholar, www.cdc.gov, www.fda.gov, and who.int. Areas covered: Toxicity vexations of HCQ; pharmaceutical perspectives on new advances in drug delivery approaches; computational modeling (PBPK and PD modeling) overtures; multipronged combination approaches for enhanced synergism with antiviral and anti-inflammatory agents; immuno-boosting effects. Expertcommentary: Harnessing the multipronged pharmaceutical perspectives will optimistically help the researchers, scientists, biotech, and pharmaceutical companies to bring new horizons in the safe and efficacious utilization of HCQ alone or in combination with remdesivir and immunomodulatory molecules like bovine lactoferrin in a fight against COVID-19. Combinational therapies with free forms or nanomedicine based targeted approaches can act synergistically to boost host immunity and stop SARS-CoV-2 replication and invasion to impede the infection. © 2021 Informa UK Limited, trading as Taylor & Francis Group.

Item Type:	Journal Article
Publication:	Expert Review of Clinical Pharmacology
Publisher:	Taylor and Francis Ltd.
Additional Information:	The copyright for this article belongs to Taylor and Francis Ltd.
Department/Centre:	Division of Mechanical Sciences > Materials Engineering (formerly Metallurgy)
Date Deposited:	27 Aug 2021 11:45
Last Modified:	30 Aug 2021 10:59
URI:	http://eprints.iisc.ac.in/id/eprint/69557

Actions (login required)

View Item